BiotechTube

Budigalimab + Placebo + Budigalimab + Placebo

Phase 1Completed
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Human Immunodeficiency Virus (HIV)

Conditions

Human Immunodeficiency Virus (HIV)

Trial Timeline

Mar 15, 2021 → Oct 11, 2022

NCT ID
NCT04799353

About Budigalimab + Placebo + Budigalimab + Placebo

Budigalimab + Placebo + Budigalimab + Placebo is a phase 1 stage product being developed by AbbVie for Human Immunodeficiency Virus (HIV). The current trial status is completed. This product is registered under clinical trial identifier NCT04799353. Target conditions include Human Immunodeficiency Virus (HIV).

What happened to similar drugs?

14 of 20 similar drugs in Human Immunodeficiency Virus (HIV) were approved

Approved (14) Terminated (4) Active (6)
✅lopinavir/ritonavirAbbVieApproved
✅emtricitabine/tenofovir disoproxil fumarateMerckApproved
✅Human Papillomavirus 9-valent Vaccine, RecombinantMerckApproved
✅3-drug anti-HIV therapy + RaltegravirMerckApproved
✅GardasilMerckApproved
✅RaltegravirMerckApproved
✅RaltegravirMerckApproved

Hype Score Breakdown

Clinical
6
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04799353Phase 1Completed

Competing Products

20 competing products in Human Immunodeficiency Virus (HIV)

See all competitors
ProductCompanyStageHype Score
mRNA-1653ModernaPhase 1
0
mRNA-1653ModernaPhase 1
0
mRNA-1345ModernaPhase 1
0
Influenza vaccine, split inactivatedComac MedicalPhase 1
19
CS-8958 + CS-8958 + oseltamivir phosphateDaiichi SankyoPhase 3
40
GSK1265744 30mg + Placebo + GSK1265744 5mgShionogiPhase 2
35
DolutegravirShionogiPhase 3
40
GSK1349572 + efavirenzShionogiPhase 2
35
Dolutegravir + Rlipivirine + GSK1265744ShionogiPhase 1
29
Dolutegravir 50 mg tablet + Dolutegravir 50 mg oral granulesShionogiPhase 1
29
Dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg + Dolutegravir 50 mg + abacavir 600 mg/lamivudine 300 mgShionogiPhase 1
29
GSK1349572 (dolutegravir) + raltegravirShionogiPhase 3
40
Ortho-Cyclen + Dolutegravir + PlaceboShionogiPhase 1
29
GSK1349572 + Placebo + Iohexol Injection + Para-aminohippurate infusionShionogiPhase 1
29
dolutegravirShionogiPhase 3
40
Dolutegravir + Atripla + Abacavir/Lamivudine + Abacavir/Lamivudine Placebo + Dolutegravir placebo + Atripla placeboShionogiPhase 3
40
GSK1349572 + EfavirenzShionogiPhase 1
29
GSK1349572ShionogiPhase 1
29
GSK1349572 + PlaceboShionogiPhase 2
35
Dolutegravir + MethadoneShionogiPhase 1
29